Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Abbott Healthcare Products B.V.

🇳🇱Netherlands

Country: 🇳🇱Netherlands

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Effect of Fenofibrate on Kidney Function: a Six-week Randomized Cross-over Trial in Healthy People

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Placebo
Drug: Fenofibrate 160 mg tablet

First Posted Date: 2007-10-15

Last Posted Date: 2015-01-19

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT00543647

Locations: 🇬🇧
Site 1, London, United Kingdom

BMS-646256 in Obese and Overweight Type 2 Diabetics

Phase 2

Withdrawn

Conditions: Obesity and Type 2 Diabetes

Interventions: Drug: ibipinabant

First Posted Date: 2007-10-10

Last Posted Date: 2008-01-09

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 600

Registration Number: NCT00541567

Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Phase 3

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Pancrelipase Delayed Release
Drug: Placebo Comparator

First Posted Date: 2007-08-02

Last Posted Date: 2010-06-03

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 35

Registration Number: NCT00510484

Locations: 🇺🇸
Site 11, Long Beach, California, United States
🇺🇸
Site 10, Los Angeles, California, United States
🇺🇸
Site 13, San Francisco, California, United States

and more 20 locations

Acceptability Study of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Type 2 Diabetes and Dyslipidemia

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Dyslipidemia

First Posted Date: 2007-06-22

Last Posted Date: 2007-09-03

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 29

Registration Number: NCT00490178

Locations: 🇫🇷
Site 3, Marseille, France
🇫🇷
Site 1, Nantes, France
🇫🇷
Site 2, Tours, France

Annual Study to Investigate Influenza Vaccine Due to New Virus Strains for the 2007/2008 Influenza Season in Europe

Phase 3

Completed

Conditions: Healthy Volunteers

First Posted Date: 2007-05-30

Last Posted Date: 2009-01-30

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 120

Registration Number: NCT00479921

Locations: 🇧🇪
Site 1, Tessenderlo, Belgium
🇩🇪
Site 2, Hamburg, Germany

A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy

Phase 3

Completed

Conditions: Chronic Pancreatitis
Pancreatectomy
Pancreatic Exocrine Insufficiency

Interventions: Drug: Pancrelipase delayed release capsule
Drug: Placebo Comparator

First Posted Date: 2006-12-22

Last Posted Date: 2011-08-10

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 52

Registration Number: NCT00414908

Locations: 🇺🇸
Site 9, Scottsdale, Arizona, United States
🇺🇸
Site 22, Bristol, Connecticut, United States
🇺🇸
Site 7, Tampa, Florida, United States

and more 27 locations

An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.

Phase 3

Completed

Conditions: Advanced Stage Parkinson's Disease

Interventions: Drug: Pardoprunox

First Posted Date: 2006-12-04

Last Posted Date: 2010-09-13

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 140

Registration Number: NCT00407095

Locations: 🇺🇸
S308.3.007 Site # 220, LaJolla, California, United States
🇺🇸
S308.3.007 Site # 211, San Francisco, California, United States
🇺🇸
S308.3.007 Site # 214, Fort Lauderdale, Florida, United States

and more 84 locations

SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations

Phase 3

Completed

Conditions: Advanced Stage Parkinson's Disease

Interventions: Drug: Levodopa (Pardoprunox)
Drug: Placebo Comparator

First Posted Date: 2006-12-04

Last Posted Date: 2015-02-27

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 295

Registration Number: NCT00406588

Locations: 🇺🇸
Site 223, Birmingham, Alabama, United States
🇺🇸
Site 220, LaJolla, California, United States
🇺🇸
Site 211, San Francisco, California, United States

and more 84 locations

Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients

Phase 3

Terminated

Conditions: Schizophrenia

Interventions: Drug: Bifeprunox
Drug: Quetiapine

First Posted Date: 2006-11-06

Last Posted Date: 2008-06-04

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 83

Registration Number: NCT00396214

Locations: 🇺🇸
Site 313, Anaheim, California, United States
🇺🇸
Site 333, Anaheim, California, United States
🇺🇸
Site 323, Cerritos, California, United States

and more 148 locations

Comparison of the Combination of Fenofibrate and Simvastatin Versus Atorvastatin

Phase 3

Completed

Conditions: Hyperlipidemia

Interventions: Drug: fenofibrate / simvastatin
Drug: Atorvastatin

First Posted Date: 2006-08-15

Last Posted Date: 2009-07-08

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 516

Registration Number: NCT00362934

Locations: 🇧🇬
Site 501, Haskovo, Bulgaria
🇧🇬
Site 505, Pleven, Bulgaria
🇧🇬
Site 503, Plovdiv, Bulgaria

and more 65 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy